A
Amandeep Sahota
Researcher at Kaiser Permanente
Publications - 34
Citations - 674
Amandeep Sahota is an academic researcher from Kaiser Permanente. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 9, co-authored 26 publications receiving 527 citations. Previous affiliations of Amandeep Sahota include University of Southern California.
Papers
More filters
Journal ArticleDOI
Foreign-body ingestion: characteristics and outcomes in a lower socioeconomic population with predominantly intentional ingestion
TL;DR: Foreign-body ingestions in an urban county hospital occurred primarily in psychiatric patients who had repeated episodes of intentional ingestions, and strategies to prevent ingestions and delays in endoscopic management are needed.
Journal ArticleDOI
Does Capsule Endoscopy Improve Outcomes in Obscure Gastrointestinal Bleeding? Randomized Trial Versus Dedicated Small Bowel Radiography
TL;DR: The significant improvement in diagnostic yield with capsule endoscopy may not translate into improved outcomes in a population with obscure GI bleeding.
Journal ArticleDOI
Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment.
Mei Lu,Yueren Zhou,Irina V. Haller,Robert J. Romanelli,Jeffrey J. VanWormer,Carla V. Rodriguez,Heather Anderson,Joseph A. Boscarino,Mark A Schmidt,Yihe G. Daida,Amandeep Sahota,Jennifer Vincent,Christopher L. Bowlus,Keith D. Lindor,Talan Zhang,Sheri Trudeau,Jia Li,Loralee B Rupp,Stuart C. Gordon +18 more
TL;DR: It is found that the prevalence of PBC increased from 2004 through 2014, despite steady incidence, and patient demographic and clinical characteristics, as well as UDCA treatment, affected mortality.
Journal ArticleDOI
Incidence of Nonalcoholic Fatty Liver Disease in Children: 2009-2018.
Amandeep Sahota,Warren L. Shapiro,Kimberly P. Newton,Kimberly P. Newton,Steven T. Kim,Joanie Chung,Jeffrey B. Schwimmer,Jeffrey B. Schwimmer +7 more
TL;DR: The study of a large integrated health care system in southern California revealed that the incidence of NAFLD in children is increasing, although many children may remain undiagnosed.
Journal ArticleDOI
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.
Kris V. Kowdley,Vinay Sundaram,Christie Y. Jeon,Kamran Qureshi,Nyan L. Latt,Amandeep Sahota,Stephen Lott,Michael P. Curry,Naoky Tsai,Nathorn Chaiyakunapruk,Y. Lee,Jörg Petersen,Peter Buggisch +12 more
TL;DR: An 8‐week duration of treatment with LDV/SOF is highly effective in properly selected patients; greater use of this regimen is recommended.